What was the first GLP-1 agonist?

Exenatide, a synthetic form of exendin-4 from Gila monster venom, which resists DPP-4 naturally because it carries glycine where human GLP-1 has alanine.

Why did the field stop extending half-life?

Once weekly dosing was achieved, duration stopped being the constraint. Effect size became the limit, so development turned to adding receptors.

Do the newer compounds have fewer side effects?

No. Gastrointestinal effects follow from GLP-1 receptor pharmacology itself and have persisted across every generation.

Retatrutide vs First-Generation Incretins

The short answer

Each generation addressed the previous one's constraint. Exenatide showed a protease-resistant GLP-1 agonist was possible. Liraglutide added albumin binding. Semaglutide extended it to weekly. Tirzepatide and retatrutide then added receptors rather than duration.

Key facts

Exenatide: Gila monster venom; natural DPP-4 resistance
Liraglutide: C16 palmitic; daily
Semaglutide: Aib8 + C18 diacid; weekly
Tirzepatide: Added GIP
Retatrutide: Added glucagon
Pattern: Duration first, then receptors

The first problem was survival

Native GLP-1 has a half-life of one to two minutes because DPP-4 removes its first two residues. Exenatide solved this by accident of biology: it is exendin-4 from Gila monster venom, carrying glycine where human GLP-1 has alanine, which DPP-4 cannot process. The first workable GLP-1 agonist was found rather than designed.

Then the problem was duration

Protease resistance does not prevent renal filtration. Liraglutide attached a C16 palmitic acid to bind albumin, reaching about 13 hours, enough for daily dosing. Semaglutide combined a stronger C18 diacid with an Aib substitution blocking DPP-4 directly, reaching roughly a week. Two generations of the same idea at increasing intensity.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

Then the constraint changed

Once weekly dosing was achieved, extending duration further stopped being the bottleneck. Effect size became the limit, and the field turned from pharmacokinetics to pharmacology, adding receptors rather than adding hours. Tirzepatide added GIP; retatrutide added glucagon.

What retatrutide inherits

All of it. The albumin-binding lipid is liraglutide's idea at semaglutide's intensity. The protease-resistant design descends from exendin-4's accidental glycine. The GIP scaffold is tirzepatide's. Retatrutide is not a departure from the first-generation compounds so much as the accumulation of every solution they produced.

What stayed constant

Gastrointestinal adverse effects, at every generation and every receptor combination. They follow from GLP-1 receptor pharmacology itself (delayed gastric emptying and area postrema signalling) rather than from any design decision, which is why thirty years of engineering has not removed them.

And what changed direction

Orforglipron and aleniglipron abandon the peptide entirely, trading effect size for oral administration. That is the first real branch in the lineage rather than another step along it, and it is why 2026 looks like the year the field split rather than advanced.

Frequently asked questions

What was the first GLP-1 agonist?: Exenatide, a synthetic form of exendin-4 from Gila monster venom, which resists DPP-4 naturally because it carries glycine where human GLP-1 has alanine.
Why did the field stop extending half-life?: Once weekly dosing was achieved, duration stopped being the constraint. Effect size became the limit, so development turned to adding receptors.
Do the newer compounds have fewer side effects?: No. Gastrointestinal effects follow from GLP-1 receptor pharmacology itself and have persisted across every generation.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

How the Incretin Field Got Here